LeadStory
HealthEconomy

Reuters

Analysis shines new light on weight loss drug use

Reuters ·
Reuters
Reuters

Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later, according to an analysis provided to Reuters that also showed a steady decline in use over time. The decline in use is spurring a debate over the drugs’ cost to patients, employers and government health plans.